The National Medical Products Administration (NMPA) of China has officially approved Nerivio®, a smartphone-controlled wearable device for the treatment of acute migraine. The clearance marks a major step forward for patients seeking non-drug alternatives to manage this debilitating neurological condition.
A Drug-Free Migraine Solution
Developed by Theranica and distributed in partnership with Pier 88 Health, Nerivio® leverages Remote Electrical Neuromodulation (REN) technology. Worn on the upper arm, the device delivers carefully controlled pulses that activate the body’s conditioned pain modulation response. Each treatment session is initiated and monitored via a mobile app, giving patients more autonomy and convenience in managing migraine attacks.
Clinical Backing and Patient Benefits
Unlike conventional migraine therapies that rely on pharmaceuticals, Nerivio® offers a drug-free approach with minimal side effects. Clinical trials and real-world evidence have shown its effectiveness in reducing migraine pain and associated symptoms, particularly for patients who cannot tolerate or do not respond to medications.
Expanding Global Footprint
The approval adds China—one of the world’s largest healthcare markets—to Nerivio®’s growing global reach. It also reflects the increasing acceptance of digital therapeutics and wearable health technologies, as health systems adopt innovative solutions for managing chronic conditions.
Milestone for Neuromodulation Therapies
For millions of migraine sufferers in China, Nerivio® offers new hope for relief while reducing reliance on traditional medications. For Theranica and Pier 88 Health, the milestone underscores their mission to expand access to neuromodulation-based treatments worldwide.
